Inari Medical, Inc. (NARI) Reports In-Line Q2 EPS; Guides Revenue Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Inari Medical Reports Second Quarter 2021 Financial Results
August 10, 2021 4:01 PM EDTIRVINE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021.
Second Quarter Revenue and Business Highlights:
Treated a record number of patients, with revenue of $63.5 million for the second quarter of 2021, up 11% sequentially and 150% year-over-year.Announced FDA clearance of FlowSaver, enabling bloodless... More